A new research paper was published in Volume 18 of Aging-US on February 6, 2026, titled "Causal effects of inflammation on long-term mortality: a Mendelian randomization study." ...
Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...
Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results